Theranostic research of radiolabeled prostate-specific membrane antigen ligands in metastatic castra-tion-resistant prostate cancer
10.3760/cma.j.issn.2095-2848.2018.12.016
- VernacularTitle:放射性核素标记前列腺特异膜抗原配体对转移性去势抵抗性前列腺癌诊治的研究进展
- Author:
Liqiang ZHOU
1
;
Jing CHEN
Author Information
1. 华中科技大学同济医学院附属同济医院核医学科
- Keywords:
Prostatic neoplasms;
castration-resistant;
Radioactive tracers;
Prostate-specific membrane antigen;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2018;38(12):828-832
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most common cancer among males. Advanced prostate cancer could develop into metastatic castration-resistant prostate cancer (mCRPC), which is a challenge in the di-agnosis and treatment. The prognosis and quality of life of patients can be significantly improved by using ra-diolabeled prostate-specific membrane antigen ( PSMA) ligands for localization and targeted therapy of mCRPC. This review summarizes the research progress of radiolabeled PSMA ligands in theranostics of mCRPC including SPECT imaging, PET imaging, and brachytherapy.
